261 related articles for article (PubMed ID: 35381946)
1. Interconnections of fibroblast growth factor 23 and klotho with erythropoietin and hypoxia-inducible factor.
Afsar B; Kanbay M; Afsar RE
Mol Cell Biochem; 2022 Jul; 477(7):1973-1985. PubMed ID: 35381946
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.
Daryadel A; Bettoni C; Haider T; Imenez Silva PH; Schnitzbauer U; Pastor-Arroyo EM; Wenger RH; Gassmann M; Wagner CA
Pflugers Arch; 2018 Oct; 470(10):1569-1582. PubMed ID: 29961920
[TBL] [Abstract][Full Text] [Related]
3. C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23.
Roszko KL; Brown S; Pang Y; Huynh T; Zhuang Z; Pacak K; Collins MT
J Bone Miner Res; 2021 Feb; 36(2):315-321. PubMed ID: 33049075
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
5. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.
Flamme I; Ellinghaus P; Urrego D; Krüger T
PLoS One; 2017; 12(10):e0186979. PubMed ID: 29073196
[TBL] [Abstract][Full Text] [Related]
6. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia.
van Vuren AJ; Eisenga MF; van Straaten S; Glenthøj A; Gaillard CAJM; Bakker SJL; de Borst MH; van Wijk R; van Beers EJ
Blood Adv; 2020 Apr; 4(8):1678-1682. PubMed ID: 32324886
[TBL] [Abstract][Full Text] [Related]
7. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.
Hanudel MR; Eisenga MF; Rappaport M; Chua K; Qiao B; Jung G; Gabayan V; Gales B; Ramos G; de Jong MA; van Zanden JJ; de Borst MH; Bakker SJL; Nemeth E; Salusky IB; Gaillard CAJM; Ganz T
Nephrol Dial Transplant; 2019 Dec; 34(12):2057-2065. PubMed ID: 30007314
[TBL] [Abstract][Full Text] [Related]
8. FGF23 Regulates Bone Mineralization in a 1,25(OH)2 D3 and Klotho-Independent Manner.
Murali SK; Roschger P; Zeitz U; Klaushofer K; Andrukhova O; Erben RG
J Bone Miner Res; 2016 Jan; 31(1):129-42. PubMed ID: 26235988
[TBL] [Abstract][Full Text] [Related]
9. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
Noonan ML; Ni P; Agoro R; Sacks SA; Swallow EA; Wheeler JA; Clinkenbeard EL; Capitano ML; Prideaux M; Atkins GJ; Thompson WR; Allen MR; Broxmeyer HE; White KE
J Bone Miner Res; 2021 Jun; 36(6):1117-1130. PubMed ID: 33592127
[TBL] [Abstract][Full Text] [Related]
10. The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research.
van Vuren AJ; Gaillard CAJM; Eisenga MF; van Wijk R; van Beers EJ
Front Physiol; 2019; 10():304. PubMed ID: 30971944
[TBL] [Abstract][Full Text] [Related]
11. α-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent.
Erben RG
Curr Opin Nephrol Hypertens; 2018 Jul; 27(4):229-235. PubMed ID: 29851418
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 23, klotho and heparin.
Thomas SM; Li Q; Faul C
Curr Opin Nephrol Hypertens; 2023 Jul; 32(4):313-323. PubMed ID: 37195242
[TBL] [Abstract][Full Text] [Related]
13. FGF23-Klotho signaling axis in the kidney.
Erben RG; Andrukhova O
Bone; 2017 Jul; 100():62-68. PubMed ID: 27622885
[TBL] [Abstract][Full Text] [Related]
14. C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23.
Hu MC; Reneau JA; Shi M; Takahashi M; Chen G; Mohammadi M; Moe OW
Am J Physiol Renal Physiol; 2024 Apr; 326(4):F584-F599. PubMed ID: 38299214
[TBL] [Abstract][Full Text] [Related]
15. Update on FGF23 and Klotho signaling.
Erben RG
Mol Cell Endocrinol; 2016 Sep; 432():56-65. PubMed ID: 27178987
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the Fibroblast Growth Factor 23/α-Klotho Axis in Peripheral Blood Mononuclear Cell Inflammation in Alzheimer's Disease.
Li B; Zhou M; Peng J; Yang Q; Chu J; Li R; Jiang Y
Immunol Invest; 2022 Jul; 51(5):1471-1484. PubMed ID: 34503373
[TBL] [Abstract][Full Text] [Related]
17. Intact FGF23 and α-Klotho during acute inflammation/sepsis in CKD patients.
Dounousi E; Torino C; Pizzini P; Cutrupi S; Panuccio V; D'Arrigo G; Abd ElHafeez S; Tripepi G; Mallamaci F; Zoccali C
Eur J Clin Invest; 2016 Mar; 46(3):234-41. PubMed ID: 26728476
[TBL] [Abstract][Full Text] [Related]
18. FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model.
Xiao Z; King G; Mancarella S; Munkhsaikhan U; Cao L; Cai C; Quarles LD
JCI Insight; 2019 Dec; 4(23):. PubMed ID: 31801907
[TBL] [Abstract][Full Text] [Related]
19. Klotho converts canonical FGF receptor into a specific receptor for FGF23.
Urakawa I; Yamazaki Y; Shimada T; Iijima K; Hasegawa H; Okawa K; Fujita T; Fukumoto S; Yamashita T
Nature; 2006 Dec; 444(7120):770-4. PubMed ID: 17086194
[TBL] [Abstract][Full Text] [Related]
20. Klotho/FGF23 Axis in CKD.
Tsuchiya K; Nagano N; Nitta K
Contrib Nephrol; 2015; 185():56-65. PubMed ID: 26023015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
